- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke
The GUARD-AF trial promotes heightened knowledge of stroke risk among patients with atrial fibrillation by analyzing, evaluating, and distributing important data back to practitioners, which can possibly reduce the incidence of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
The GUARD-AF trial promotes heightened knowledge of stroke risk among patients with atrial fibrillation by analyzing, evaluating, and distributing important data back to practitioners, which can possibly reduce the incidence of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
Transcript
Can you discuss the implementation of the GUARD-AF trial and why a study focusing on preventive measures associated with the likelihood of related adverse outcomes (e.g. stroke) is warranted?
GUARD-AF is a potentially practice informing study that could help change the way in which medicine is practiced in reducing stroke in patients with atrial fibrillation (AF). AF is a condition with a high unmet need. It's estimated that about 8 million people in the United States have atrial fibrillation; but importantly, many people are not aware that they have atrial fibrillation. Many people find that stroke is the first sign of their atrial fibrillation, and strokes in people with AF are severe. In about 25% of individuals, they will die prematurely in the first 30 days after a stroke. However, there haven't been any studies that have demonstrated that screening for AF actually reduces the risk of stroke versus usual care. So, GUARD-AF is a study that will provide important information on that question.
Maybe I could take a few moments to describe the GUARD-AF study. GUARD-AF is a study that compares screening for atrial fibrillation versus standard of care. It'll randomize 52,000 patients over 300 US primary care centers—these will be patients who are on Medicare. Now patients who are randomized to receive screening will administer a patch for 14 days which will collect information on their heart rhythm. This data will be analyzed, evaluated, and fed back to the practitioner. The practitioner can then make an informed judgment on how best to treat that patient moving forward. So, GUARD-AF will hopefully provide important information on whether that intervention, that is screening for stroke or screening for atrial fibrillation, will actually reduce the incidence of stroke.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
